Pathology & Oncology Research

, Volume 25, Issue 2, pp 635–646 | Cite as

Desumoylating Isopeptidase 2 (DESI2) Inhibits Proliferation and Promotes Apoptosis of Pancreatic Cancer Cells through Regulating PI3K/AKT/mTOR Signaling Pathway

  • Xi Ou
  • Guang-tao Zhang
  • Zhe Xu
  • Jing-sen Chen
  • Yong Xie
  • Ji-Kui LiuEmail author
  • Xiao-Ping Liu
Original Article


This study aimed to investigate the effects of desumoylating isopeptidase 2 (DESI2) on tumor cell proliferation, apoptosis and invasion of pancreatic cancer, and to assess the signaling pathway involved. Overexpression and silence of DESI2 were designed and the experiments were divided into 5 groups: a normal control group, an interference control group (shRNA-NC); an interference group (sh-DESI2); an overexpression control group (NC), an overexpression group (DESI2). Quantitative real time polymerase chain reaction (qRT-PCR) was used to screen the appropriate interference sequence. The silencing and overexpression of DESI2 were confirmed by qRT-PCR and western blotting. Cell cycling, apoptosis, invasion, and the expression of phosphatidylinositol-3-kinase (PI3K)-protein kinase B (AKT)-mammalian target of rapamycin (mTOR) pathway and caspase 3 were measured. Overexpression and silence of DESI2 were successfully designed in two pancreatic cancer cells, and the interference effect of sh-DESI2–3 showed the best silencing effects. The biological activities of DESI2 were detected in both ASPC-1 and PANCE-1 cells. Our results showed that cell proliferation was significantly increased in the sh-DESI2 group, while decreased in DESI2 group compared with the control group in both cell lines. In ASPC-1 cells, the events in G1 phase decreased and in S phase increased obviously in the sh-DESI2 group, compared with control group. An opposite result was found when DESI2 was overexpressed. In PANCE-1 cells, the events in G2 phase were higher in the sh-DESI2 group, while in the DESI2 group was significantly lower than that in control group. In ASPC-1 and PANCE-1 cells, sh-DESI2 group showed decreased apoptosis, increased cell invasion and increased expression of AKT, p-Akt, PI3K, p-PI3K, p-mTOR and mTOR and decreased caspase 3 expression compared with the control group, while overexpression of DESI2 leaded to increased apoptosis, decreased cell invasion and reduced expression of AKT, p-Akt, PI3K, p-PI3K, p-mTOR and mTOR and increased expression of caspase 3. DESI2 regulates the proliferation and apoptosis of pancreatic cancer cells through PI3K/AKT/mTOR signaling pathway.


Desumoylating isopeptidase 2 Pancreatic cancer Phosphatidylinositide 3-kinases AKT mTOR 


Author Contributions

XO, GZ, ZX, JC, YX and JL did the experiments and analyzed the data. X Liu YC and XO designed the study and wrote the manuscript.


The present study was supported by the Science and Technology Development Fund Project of Shenzhen (grant no. JCYJ20160428164539088), the Sanming Project of Medicine in Shenzhen (grant no. SZSM201612021) and the Science and Technology Developing Project of Guangdong Province (grant no. 2017B090904010).


  1. 1.
    Seipel AH, Wiklund F, Wiklund NP, Egevad L (2013) Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens. Virchows Arch 462(4):429–436. CrossRefGoogle Scholar
  2. 2.
    Lin C, Yan H, Yang J, Li L, Tang M, Zhao X, Nie C, Luo N, Wei Y, Yuan Z (2017) Combination of DESI2 and IP10 gene therapy significantly improves therapeutic efficacy against murine carcinoma. Oncotarget 8(34):56281–56295. Google Scholar
  3. 3.
    Shen CC, Cui XY, He Y, Kang YH, Yi C, Yang JL, Gou LT (2015) High phosphorylation status of AKT/mTOR signal in DESI2-reduced pancreatic ductal adenocarcinoma. Pathol Oncol Res 21(2):267–272. CrossRefGoogle Scholar
  4. 4.
    Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF (2013) Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 369(18):1691–1703. CrossRefGoogle Scholar
  5. 5.
    Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R (2012) PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol Off J Am Soc Clin Oncol 30(8):777–782. CrossRefGoogle Scholar
  6. 6.
    Zhu G, Liu Y, Wang Y, Bi X, Baudry M (2015) Different patterns of electrical activity lead to long-term potentiation by activating different intracellular pathways. J Neurosci 35(2):621–633. CrossRefGoogle Scholar
  7. 7.
    Li J, Yang S, Zhu G (2017) Postnatal calpain inhibition elicits cerebellar cell death and motor dysfunction. Oncotarget 8(50):87997–88007. Google Scholar
  8. 8.
    Lastwika KJ, Wilson W 3rd, Li QK, Norris J, Xu H, Ghazarian SR, Kitagawa H, Kawabata S, Taube JM, Yao S, Liu LN, Gills JJ, Dennis PA (2016) Control of PD-L1 expression by oncogenic activation of the AKT-mTOR pathway in non-small cell lung Cancer. Cancer Res 76(2):227–238. CrossRefGoogle Scholar
  9. 9.
    Li J, Liang X, Yang X (2012) Ursolic acid inhibits growth and induces apoptosis in gemcitabine-resistant human pancreatic cancer via the JNK and PI3K/Akt/NF-kappaB pathways. Oncol Rep 28(2):501–510. CrossRefGoogle Scholar
  10. 10.
    Zhu G, Wang X, Wu S, Li Q (2012) Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+−induced human neuroblastoma SH-SY5Y cell death. Neurochem Int 60(4):400–408. CrossRefGoogle Scholar
  11. 11.
    Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, Whiting M, Madan A, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones SJ, Marra MA, Mammalian Gene Collection Program T (2002) Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci U S A 99(26):16899–16903. CrossRefGoogle Scholar
  12. 12.
    Yan F, Ruan XZ, Yang HS, Yao SH, Zhao XY, Gou LT, Ma FX, Yuan Z, Deng HX, Wei YQ (2010) Identification, characterization, and effects of Xenopus laevis PNAS-4 gene on embryonic development. J Biomed Biotechnol 2010:134764–134769. CrossRefGoogle Scholar
  13. 13.
    Yan F, Gou L, Yang J, Chen L, Tong A, Tang M, Yuan Z, Yao S, Zhang P, Wei Y (2009) A novel pro-apoptosis gene PNAS4 that induces apoptosis in A549 human lung adenocarcinoma cells and inhibits tumor growth in mice. Biochimie 91(4):502–507. CrossRefGoogle Scholar
  14. 14.
    Yuan Z, Guo W, Yang J, Li L, Wang M, Lei Y, Wan Y, Zhao X, Luo N, Cheng P, Liu X, Nie C, Peng Y, Tong A, Wei Y (2015) PNAS-4, an early DNA damage response gene, induces S phase arrest and apoptosis by activating checkpoint kinases in lung Cancer cells. J Biol Chem 290(24):14927–14944. CrossRefGoogle Scholar
  15. 15.
    Li L, Chen DB, Lin C, Cao K, Wan Y, Zhao XY, Nie CL, Yuan Z, Wei YQ (2013) hPNAS-4 inhibits proliferation through S phase arrest and apoptosis: underlying action mechanism in ovarian cancer cells. Apoptosis 18(4):467–479. CrossRefGoogle Scholar
  16. 16.
    Roy SK, Srivastava RK, Shankar S (2010) Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 5:10. CrossRefGoogle Scholar
  17. 17.
    Yuan Z, Yan F, Wang YS, Liu HY, Gou LT, Zhao XY, Lai ST, Deng HX, Li J, Ding ZY, Xiong SQ, Kan B, Mao YQ, Chen LJ, Wei YQ, Zhao X (2009) PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin. Cancer Chemother Pharmacol 65(1):13–25. CrossRefGoogle Scholar
  18. 18.
    Qi X, Song X, Liu P, Yi T, Li S, Xie C, Zheng Y, Bai Y, Sun C, Wei Y, Zhao X (2011) Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer. Oncol Rep 26(3):703–710. Google Scholar
  19. 19.
    Hou S, Zhao Z, Yan F, Chen X, Deng H, Chen X, Wang Y, Wei Y (2009) Genetic transfer of PNAS-4 induces apoptosis and enhances sensitivity to gemcitabine in lung cancer. Cell Biol Int 33(3):276–282. CrossRefGoogle Scholar
  20. 20.
    Yuan Z, Liu H, Yan F, Wang Y, Gou L, Nie C, Ding Z, Lai S, Zhao Y, Zhao X, Li J, Deng H, Mao Y, Chen L, Wei Y, Zhao X (2009) Improved therapeutic efficacy against murine carcinoma by combining honokiol with gene therapy of PNAS-4, a novel pro-apoptotic gene. Cancer Sci 100(9):1757–1766. CrossRefGoogle Scholar
  21. 21.
    Flanagan L, Meyer M, Fay J, Curry S, Bacon O, Duessmann H, John K, Boland KC, McNamara DA, Kay EW, Bantel H, Schulze-Bergkamen H, Prehn JH (2016) Low levels of Caspase-3 predict favourable response to 5FU-based chemotherapy in advanced colorectal cancer: Caspase-3 inhibition as a therapeutic approach. Cell Death Dis 7:e2087. CrossRefGoogle Scholar
  22. 22.
    Baharara J, Ramezani T, Divsalar A, Mousavi M, Seyedarabi A (2016) Induction of apoptosis by green synthesized gold nanoparticles through activation of Caspase-3 and 9 in human cervical Cancer cells. Avicenna J Med Biotechnol 8(2):75–83Google Scholar
  23. 23.
    Dolka I, Krol M, Sapierzynski R (2016) Evaluation of apoptosis-associated protein (Bcl-2, Bax, cleaved caspase-3 and p53) expression in canine mammary tumors: an immunohistochemical and prognostic study. Res Vet Sci 105:124–133. CrossRefGoogle Scholar
  24. 24.
    Xu Z, Zhang F, Bai C, Yao C, Zhong H, Zou C, Chen X (2017) Sophoridine induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in human pancreatic cancer cells. J Exp Clin Cancer Res 36(1):124. CrossRefGoogle Scholar
  25. 25.
    Cheng X, Wang B, Jin Z, Ma D, Yang W, Zhao R, Jing X, Shen B, Peng C, Qiu W (2016) Pseudomonas aeruginosa-mannose-sensitive hemagglutinin inhibits pancreatic cancer cell proliferation and induces apoptosis via the EGFR pathway and caspase signaling. Oncotarget 7(47):77916–77925. CrossRefGoogle Scholar
  26. 26.
    Chiu TL, Su CC (2017) Tanshinone IIA increases protein expression levels of PERK, ATF6, IRE1alpha, CHOP, caspase3 and caspase12 in pancreatic cancer BxPC3 cellderived xenograft tumors. Mol Med Rep 15(5):3259–3263. CrossRefGoogle Scholar
  27. 27.
    Castel P, Toska E, Zumsteg ZS, Carmona FJ, Elkabets M, Bosch A, Scaltriti M (2014) Rationale-based therapeutic combinations with PI3K inhibitors in cancer treatment. Mol Cell Oncol 1(3):e963447. CrossRefGoogle Scholar
  28. 28.
    Wang MC, Jiao M, Wu T, Jing L, Cui J, Guo H, Tian T, Ruan ZP, Wei YC, Jiang LL, Sun HF, Huang LX, Nan KJ, Li CL (2016) Polycomb complex protein BMI-1 promotes invasion and metastasis of pancreatic cancer stem cells by activating PI3K/AKT signaling, an ex vivo, in vitro, and in vivo study. Oncotarget 7(8):9586–9599. Google Scholar
  29. 29.
    Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, Gunn S, Smetzer L, Mays TA, Kaiser B, Wick MJ, Alvarez C, Cavazos A, Mangold GL, Patnaik A (2012) The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 18(8):2316–2325. CrossRefGoogle Scholar
  30. 30.
    Gao N, Flynn DC, Zhang Z, Zhong XS, Walker V, Liu KJ, Shi X, Jiang BH (2004) G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells. Am J Physiol Cell Physiol 287(2):C281–C291. CrossRefGoogle Scholar
  31. 31.
    Liu CY, Hu MH, Hsu CJ, Huang CT, Wang DS, Tsai WC, Chen YT, Lee CH, Chu PY, Hsu CC, Chen MH, Shiau CW, Tseng LM, Chen KF (2016) Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells. Oncotarget 7(8):9135–9149. Google Scholar
  32. 32.
    Chen J, Shao R, Li F, Monteiro M, Liu JP, Xu ZP, Gu W (2015) PI3K/Akt/mTOR pathway dual inhibitor BEZ235 suppresses the stemness of colon cancer stem cells. Clin Exp Pharmacol Physiol 42(12):1317–1326. CrossRefGoogle Scholar
  33. 33.
    Eser S, Schnieke A, Schneider G, Saur D (2014) Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 111(5):817–822. CrossRefGoogle Scholar
  34. 34.
    Cheng HB, Bo Y, Shen WX, Ren XG, Tan JN, Jia ZR, Xu CL (2015) Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedeberg's Arch Pharmacol 388(6):623–634. CrossRefGoogle Scholar

Copyright information

© Arányi Lajos Foundation 2018

Authors and Affiliations

  • Xi Ou
    • 1
  • Guang-tao Zhang
    • 1
  • Zhe Xu
    • 2
  • Jing-sen Chen
    • 3
  • Yong Xie
    • 1
  • Ji-Kui Liu
    • 1
    Email author
  • Xiao-Ping Liu
    • 1
  1. 1.Department of Hepatopancreatobiliary SurgeryPeking University Shenzhen HospitalShenzhenChina
  2. 2.The Third Ward of Liver DiseaseThe Third People’s Hospital of ShenzhenShenzhenChina
  3. 3.Breast DepartmentShenzhen Maternity and Child Healthcare HospitalShenzhenChina

Personalised recommendations